Xcout IntelGenerate Biomedicines, Inc.
Generate Biomedicines, Inc. is a U.S.-based company pioneering generative biology, leveraging machine learning for the discovery and advancement of novel protein therapeutics. Their core approach involves developing drugs using protein-based modalities. The company's pipeline includes several key candidates: GB-0895, an investigational long-acting anti-TSLP monoclonal antibody designed for bi-annual dosing in severe asthma; GB-4362, an MMAE payload neutralizer monoclonal antibody; and GB-5267, a MUC16 CAR-T cell therapy. Integral to their work is the Generate Platform, a sophisticated system engineered to be versatile across diverse therapeutic areas and protein modalities. This platform combines computational innovation with scalable biohardware, allowing them to tackle therapeutic hurdles beyond the capabilities of traditional technologies. Established in 2018, the company was initially known as Generate Biologics, Inc. before rebranding to Generate Biomedicines, Inc. in February 2020. Its headquarters are located in Somerville, Massachusetts.
Subscribe to see Generate Biomedicines, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Generate Biomedicines, Inc. at a glance
Generate Biomedicines, Inc. is a biotechnology company headquartered in Somerville, United States. It is publicly listed (GENB) with a market capitalisation of $1.8B. Xcout tracks 13 named people at Generate Biomedicines, Inc., including Michael T. Nally (CEO & Director). Xcout recorded 41 job postings from Generate Biomedicines, Inc. in the last 90 days.
Generate Biomedicines, Inc. leadership
- Michael T. NallyCEO & Director
- Michael NallyChief Executive Officer
- Jason E. SilversPresident & CFO
- Jason SilversPresident Chief Financial Officer
- Aarif KhakooChief Scientific Officer
- Beth GrousChief People Officer
7 more named people on record for Generate Biomedicines, Inc., with roles, board committees and tenure — see the full roster →
Hiring at Generate Biomedicines, Inc.
Xcout recorded 41 job postings from Generate Biomedicines, Inc. in the last 90 days, from a hiring record Xcout has kept since June 2026.
The weekly hiring trend, the roles and locations behind it — see Generate Biomedicines, Inc.'s hiring signals →
Recent Generate Biomedicines, Inc. news
4 corporate events on record, with sources — see the full timeline →
Generate Biomedicines, Inc. competitors
A few of Generate Biomedicines, Inc.'s closest competitors — see the full list of competitors and alternatives →
Superluminal Medicines is a generative biology and chemistry company headquartered in Boston, Massachusetts, focused on drug discovery and development.
Antiverse is a biotechnology research company headquartered in Cardiff, Wales, that utilizes generative artificial intelligence to design functional antibodies for challenging drug targets.
Metaphore Biotechnologies, Inc. is a biotechnology company headquartered in Cambridge, Massachusetts, operating as part of Flagship Pioneering. The company focuses on therapeutic design, leveraging AI and machine learning technologies for drug discovery and development.
Great Bay Bio is a biotech company headquartered in HKSTP that drives drug development using cutting-edge technologies such as AI and big data mining.
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers. The company's pipeline further includes programs for CDK2 in ovarian, uterine, and breast cancers, alongside NEK7 for addressing a spectrum of inflammatory conditions such as Crohn's disease, neurodegenerative ailments, diabetes, and liver disease. Moreover, VAV1 is being explored as a target for autoimmune disorders, and BCL11A, a protein holding significant therapeutic relevance, is under investigation for hemoglobinopathies. Founded in 2019, Monte Rosa Therapeutics, Inc. operates from its headquarters in Boston, Massachusetts.
Engine Biosciences is a Singapore-based biotechnology company and venture-creation platform that combines machine learning, computational biology, and laboratory experimentation to discover and develop new medicines. It builds and invests in therapeutic-focused biotech companies, serving pharmaceutical and healthcare markets.
Get Generate Biomedicines, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Generate Biomedicines, Inc. in Xcout Intel
- 13 named people with titles, LinkedIn and board committees
- Weekly hiring history and the mix of roles behind it
- 4 corporate events with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access